214 related articles for article (PubMed ID: 15193140)
1. Peptidomimetic inhibitors of HIV protease.
Randolph JT; DeGoey DA
Curr Top Med Chem; 2004; 4(10):1079-95. PubMed ID: 15193140
[TBL] [Abstract][Full Text] [Related]
2. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
Poirier JM; Robidou P; Jaillon P
Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
[TBL] [Abstract][Full Text] [Related]
3. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
[TBL] [Abstract][Full Text] [Related]
4. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
5. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Jayakanthan M; Chandrasekar S; Muthukumaran J; Mathur PP
J Mol Graph Model; 2010 Jan; 28(5):455-63. PubMed ID: 19931478
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
7. Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Tomasselli AG; Heinrikson RL
Biochim Biophys Acta; 2000 Mar; 1477(1-2):189-214. PubMed ID: 10708858
[TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Choi SO; Rezk NL; Kashuba AD
J Pharm Biomed Anal; 2007 Mar; 43(4):1562-7. PubMed ID: 17236737
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
[TBL] [Abstract][Full Text] [Related]
10. Atazanavir: its role in HIV treatment.
Wood R
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):785-96. PubMed ID: 19053892
[TBL] [Abstract][Full Text] [Related]
11. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D; Schapiro JM; Brenner BG; Wainberg MA
Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
[TBL] [Abstract][Full Text] [Related]
12. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
[No Abstract] [Full Text] [Related]
13. What they say about: protease inhibitors.
Posit Aware; 2000; 11(1):48-54. PubMed ID: 11366351
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
de Mendoza C; Valer L; Bacheler L; Pattery T; Corral A; Soriano V
AIDS; 2006 Apr; 20(7):1071-4. PubMed ID: 16603864
[TBL] [Abstract][Full Text] [Related]
15. Ongoing trials in HIV protease inhibitors.
Tavel JA
Expert Opin Investig Drugs; 2000 Apr; 9(4):917-28. PubMed ID: 11060719
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Jan; 19(2):153-62. PubMed ID: 15668540
[No Abstract] [Full Text] [Related]
17. Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
AIDS Patient Care STDS; 1998 Apr; 12(4):315-6. PubMed ID: 11361959
[No Abstract] [Full Text] [Related]
18. Reviving protease inhibitors: new data and more options.
Murphy RL
J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
[No Abstract] [Full Text] [Related]
19. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Sulkowski MS; Mehta SH; Chaisson RE; Thomas DL; Moore RD
AIDS; 2004 Nov; 18(17):2277-84. PubMed ID: 15577540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]